Lupin Receives Final Approval For Zileuton Extended

Lupin announced that it has received approval for its Zileuton Extended-Release Tablets, 600 mg, from the United States Food and Drug Administration (U . S.

FDA), to market a generic equivalent of Zyflo CR Extended-Release Tablets, 600 mg, of Chiesi USA, Inc.

Lupin’s Zileuton Extended-Release Tablets, 600 mg are indicated for prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

Zileuton Extended-Release Tablets, 600 mg had annual sales of approximately USD 43 million in the U. S. –Business Standard